Skip to main content
Figure 5 | BMC Gastroenterology

Figure 5

From: Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and –experienced patients

Figure 5

Results of bayesian mixed treatment comparison for treatment experienced patients. The upper node part indicates the treatment group [Node labels: A, standard treatment (Peg-IFN-α/RBV 48 weeks); B, fixed-length treatment (FLT) with long tail (TVR 12/24 weeks/Peg-IFN-α/RBV 48 weeks); C, FLT with short tail (TVR 12 weeks/Peg-IFN-α/RBV 24 weeks); D, response-guided treatment (RGT) with tail (TVR 12 weeks/Peg-IFN-α/RBV 24 and/or 24 weeks); E, RGT without tail (TVR 12 weeks/Peg-IFN-α/RBV 12 or 36 weeks), the lower node part gives the median proportion of patients (in percent) with sustained virological response (SVR, credible 95% bayesian intervals in square brackets). Nodes with red background have not been observed and have only been simulated from the bayesian model. The edges indicate comparisons with the arrowhead indicating the comparator (i.e. baseline). The odds ratio of the respective comparison is shown with credible 95-% intervals of the bayesian analysis in square brackets. Dashed lines (and red text color) indicate comparison that was not observed but only simulated.

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us